Citigroup Inc. reissued their neutral rating on shares of C.R. Bard (NYSE:BCR) in a research note released on Monday morning, Analyst Ratings Network reports. They currently have a $124.00 target price on the stock, up from their previous target price of $123.00.
“We are adjusting our BCR estimates to reflect the continued delay in the Gore court decision and the completion of the Medafor acquisition. We are now assuming a Gore royalty start in 1Q14 and expect the Medafor acquisition to be slightly EPS accretive in 2014. For 3Q13, we have raised our Soft Tissue Repair estimates due to the full US release of Phasix resorbable mesh.,” the firm’s analyst wrote.
Shares of C.R. Bard (NYSE:BCR) traded up 1.35% on Monday, hitting $120.06. The stock had a trading volume of 158,626 shares. C.R. Bard has a 1-year low of $93.79 and a 1-year high of $121.16. The stock has a 50-day moving average of $116.9 and a 200-day moving average of $109.9. The company has a market cap of $9.503 billion and a price-to-earnings ratio of 53.53.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $1.42 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.38 by $0.04. The company had revenue of $759.90 million for the quarter, compared to the consensus estimate of $750.91 million. During the same quarter in the prior year, the company posted $1.62 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts predict that C.R. Bard will post $5.95 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Friday, November 1st. Shareholders of record on Monday, October 21st will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.71%. The ex-dividend date is Thursday, October 17th.
A number of other analysts have also recently weighed in on BCR. Analysts at Needham & Company initiated coverage on shares of C.R. Bard in a research note to investors on Wednesday, September 4th. They set a hold rating on the stock. Separately, analysts at Zacks reiterated a neutral rating on shares of C.R. Bard in a research note to investors on Tuesday, September 3rd. They now have a $121.00 price target on the stock. Finally, analysts at Bank of America Corp. reiterated a buy rating on shares of C.R. Bard in a research note to investors on Thursday, August 29th. They now have a $140.00 price target on the stock, up previously from $125.00. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the stock. C.R. Bard has an average rating of Hold and a consensus price target of $115.71.
C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.